TREATMENT OF METASTATIC COLORECTAL
CANCER (mCRC)

Introduction

About 50% to 60% of patients diagnosed with colorectal cancer develop metastases. Among these patients, 80% to 90% have unresectable liver tumors. In general, metastatic disease develops after treatment for locoregional cancer, although 20% to 34% will have a liver metastasis at the time of their primary diagnosis.

It has been estimated that more than half of all patients who die from mCRC have liver metastases at autopsy, with liver metastasis being the immediate cause of death in most patients. Patients with colorectal cancer have a poorer prognosis if they have metastases outside of the liver, more than 3 tumors, or a disease-free interval of less than 12 months following adjuvant therapy.

Chapter 6

Topic 1

Goals of Therapy and Principles of Management
ENTER

Topic 2

Continuum of Care
ENTER

Topic 3

NCCN Continuum of Care for Patients Appropriate for Intensive Therapy (Version 2.2020 – March 3, 2020)
ENTER

Topic 4

NCCN Continuum of Care for Patients NOT Appropriate for Intensive Therapy (Version 2.2020 – March 3, 2020)
ENTER